More than 80% of all cancer patients die from metastasis, not the actual primary tumour. Cancer is complex, heterogeneous and dynamic. For the patient, a cancer treatment journey drains physically, emotionally, mentally and financially. For the oncologist, it may mean questions of possible overtreatment and having to subject patients to frequent, painful biopsies. Over the course of treatment, the cancer can evolve and become resistant, making treatment decisions challenging and potentially sub-optimal.

Therefore the ability to precisely detect these changes facilitates timely diagnosis and staging of the disease; this ability is critical for precise, tailored treatment and proactive monitoring. This is where Circulating Tumour Cells (CTCs) become critically relevant.

Contact Us for more information